Previous Article | Next Article 
Journal of Virology, June 2001, p. 5036-5042, Vol. 75, No. 11
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.11.5036-5042.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Coadministration of Gamma Interferon with DNA Vaccine Expressing
Woodchuck Hepatitis Virus (WHV) Core Antigen Enhances the Specific
Immune Response and Protects against WHV Infection
Felix
Siegel,
Mengji
Lu, and
Michael
Roggendorf*
Institut für Virologie,
Universitätsklinikum Essen, Essen, Germany
Received 4 December 2000/Accepted 5 March 2001
 |
ABSTRACT |
DNA vaccinations are able to induce strong cellular immune
responses in mice and confer protection against infectious agents. However, DNA vaccination of large animals appears to be less effective and requires repeated injections of large amounts of plasmid DNA. Enhancement of the efficiency of DNA vaccines may be achieved by
coapplication of cytokine-expressing plasmids. Here we investigated, with woodchucks, whether coadministration of an expression plasmid for
woodchuck gamma interferon (IFN-
), pWIFN-
, can improve DNA vaccination with woodchuck hepatitis virus core antigen (WHcAg). Animals were immunized with pWHcIm (a plasmid expressing WHcAg) alone
or with a combination of pWHcIm and pWIFN-
using a gene gun. Six
weeks postimmunization, all animals were challenged with 105 genome equivalents of woodchuck hepatitis virus (WHV).
The antibody and lymphoproliferative immune responses to WHV proteins
were determined after immunization and after challenge. Vaccination with pWHcIm and pWIFN-
led to a pronounced lymphoproliferative response to WHcAg and protected woodchucks against subsequent virus
challenge. Two of three animals vaccinated with pWHcIm alone did not
show a detectable lymphoproliferative response to WHcAg. A low-level
WHV infection occurred in these woodchucks after challenge, as WHV DNA
was detectable in the serum by PCR. None of the pWHcIm-vaccinated animals showed an anti-WHcAg antibody response after DNA vaccination or
an anamnestic response after virus challenge. Our results indicate that
coadministration of the WIFN-
gene with pWHcIm enhanced the specific
cellular immune response and improved the protective efficacy of
WHV-specific DNA vaccines.
 |
INTRODUCTION |
Plasmid DNA vaccines are novel and
powerful tools to induce humoral and cellular immune responses which
are protective against bacterial and viral infections (25,
33; reviewed in reference 8). Altering the route of
delivery and coapplication of stimulatory molecules can be used to
improve DNA vaccines. DNA vaccines are commonly delivered by either
intramuscular injection or intradermal application using a gene gun.
The gene gun-mediated propulsion of DNA-coated gold particles into the
dermis is an attractive mode of application, since only small amounts
of plasmid DNA are needed for vaccination (13, 20, 26, 30,
31). The presence of large numbers of antigen-presenting
Langerhans cells makes the skin a major immunological inductive site
and may explain the high efficacy of gene gun vaccination (19,
29). The coapplication of plasmids expressing cytokines is an
approach to modulate immune response to DNA vaccines (3, 4, 11,
14, 15). It has been demonstrated that gamma interferon
(IFN-
) plasmids support Th1 responses and suppress Th2 responses.
Other biological effects of IFN-
include the induction of major
histocompatibility complex class I and II expression on cellular
surfaces and hence an enhancement of antigen presentation. IFN-
also
converts various cell types into nonprofessional antigen-presenting
cells and triggers the differentiation, maturation, and activation of
resting macrophages (reviewed in reference 9).
Furthermore, IFN-
supports tumor necrosis factor alpha effects in a
synergistic way. Consequently, it has been shown that the coinjection
of IFN-
and interleukin-12 expression vectors significantly enhances
the cellular immune response in mice (15).
To evaluate DNA vaccines against hepatitis B, a number of
immunogenicity studies and protection studies with different hepatitis B virus proteins have been carried out (1, 2, 7, 17, 18, 34,
35). Immunizations with plasmids expressing hepatitis B virus
surface antigen (HBsAg) and hepatitis B virus core antigen (HBcAg) have
been shown to induce high antibody titers and substantial T-cell
responses in mice (1, 2). Protection from hepadnavirus infection by intramuscular DNA immunization has been demonstrated with
ducks and woodchucks (22, 32). Antibody titers known to be
protective in humans have also been induced by DNA vaccination of
chimpanzees using a plasmid expressing HBsAg (6).
In previous studies, it has been demonstrated that an immune response
against the woodchuck hepatitis virus (WHV) core antigen (WHcAg) primed
by DNA vaccination effectively protected woodchucks against subsequent
challenge with WHV (22). As the core protein inside the
intact viral particle is covered by the surface antigen and therefore
is not accessible to neutralizing antibodies, the cellular immune
response may have played the major role in this protection. DNA
vaccinations appeared to be less effective in large animals than in
mice. Immunizations of woodchucks with a plasmid expressing WHcAg
(pWHcIm) induced only a low level of WHcAg-specific lymphoproliferative
and antibody responses. Therefore, we investigated whether
coapplication of the recently characterized woodchuck IFN-
(21) can improve the efficacy of pWHcIm-based DNA
vaccination. We demonstrated that gene gun immunization using WHcAg in
combination with woodchuck IFN-
is sufficient to induce a
lymphoproliferative immune response and to suppress viral replication after challenge with WHV.
 |
MATERIALS AND METHODS |
Woodchucks.
Adult WHV-negative woodchucks trapped in the
state of New York were purchased from North Eastern Wildlife (Ithaca,
N.Y.). Previous exposure to WHV of these woodchucks was excluded by
testing for anti-WHc, anti-WHs, and WHsAg. At the beginning of the
study, the woodchucks were between 12 and 18 months old.
Construction, purification, and expression of plasmids
pWHcIm and pWIFN
.
Plasmids pWHcIm and pWIFN
were
constructed as described earlier (21, 22). Briefly, the
core gene of WHV8 was amplified by PCR, and the PCR products were
cloned into pCRII (Invitrogen, San Diego, Calif.) according to the
manufacturer's instructions. The sequenced PCR fragment containing the
WHV core gene was isolated by digestion with EcoRI and
inserted into the EcoRI site of pcDNA3 (Invitrogen). The
integrity of the clones was verified by sequencing.
Plasmids pWHcIm and pWIFN
were prepared with a Giga plasmid
purification kit (Qiagen, Hilden, Germany). Plasmids were dissolved in
phosphate-buffered saline at a concentration of 1 mg/ml. The amount of
bacterial protein contaminants in these preparations ranged from 0 to
10 ng/ml, as determined by using micro-BCA protein assay reagent
(Pierce; Oud Beijerland, The Netherlands).
Expression was demonstrated as described earlier (
22).
Briefly, a BHK cell line and a woodchuck liver cell line, WH12/6,
were
used for transfection experiments. Transfection of cells
was
performed using lipofectamine (Gibco BRL, Eggenstein-Leopoldshafen,
Germany). Four micrograms of plasmid was incubated with 10 µg
of
lipofectamine in 100 µl of media for 45 min and was incubated
with
cells in 1 ml of Opti-Media (Gibco BRL) for 6 h at 37°C,
5%
CO
2. pWHcIm-transfected cells were maintained for 48 h at
37°C
in 5% CO
2 and fixed with acetone and methanol
(1:1). The expressed
WHcAg was detected by indirect
immunofluorescence staining using
rabbit antisera. The expression
of woodchuck IFN-

was shown in
a
bioassay.
Virus protection assay.
A virus protection assay was carried
out to measure the amounts of IFN-
. Briefly, mouse L929 or woodchuck
WH12/6 cells were seeded into 96-well microtiter plates and cultured in
100 µl of F12 medium supplemented with 10% fetal calf serum at
37°C in 5% CO2 until 100% confluent. After the culture
medium was discarded, 100 µl of F12 medium containing appropriate
dilutions of samples was added to cells for an additional incubation of
24 h. Afterwards, mouse encephalomyocarditis virus was added
to cells and incubated an additional 24 h. Cells were
stained and fixed with 0.1% crystal violet in 20% ethanol. One unit
of IFN-
was defined by its ability to protect 50% of cells per well.
Immunization of woodchucks by gene gun.
Gene gun
immunizations were delivered to the shaved groin regions of
ketamine-xylazine hydrochloride (Rompun)-anesthetized woodchucks using
a Helios Gene Gun (Bio-Rad, Hercules, Calif.). Immunizations were
performed as recommended by the manufacturer. DNA was precipitated onto
1-µm gold beads (Bio-Rad) at room temperature. Twenty-five
milligrams of gold microcarriers was measured into a 1.5-ml
microcentrifuge tube. One hundred microliters of 0.05 M spermidine
(Sigma, St. Louis, Mo.) was added, and the mixture was vortexed for 20 s and sonicated for 5 s. Fifty micrograms of pWHcIm (or 50 µg of
pWHcIm and 50 µg of pWIFN-
) was added in a maximum volume of 100 µl. The mixture was again vortexed for 20 s. While the mixture
was being vortexed at a moderate rate on a variable-speed vortexer, 100 µl of 1 M CaCl2 was added drop by drop. The DNA was
allowed to precipitate at room temperature for 10 min. The supernatant
was removed, and the gold microcarriers were washed three times with
fresh 100% ethanol. After the last wash, 3 ml of ethanol containing
0.05 mg of polyvinylpyrrolidone (Bio-Rad) was added to the mixture. The
gold microcarriers were then used to coat the inner wall of Tefzel
tubing (Bio-Rad) according to the manufacturer's protocol. Cartridges
were loaded into the gene gun. Ten cartridges were discharged per
animal (five shots with 300 lb/in2 and five shots with 400 lb/in2), delivering a total of 10 µg of pWHcIm (or 10 µg of pWHcIm and 10 µg of pWIFN-
).
WHV challenge and statistical analysis.
Six weeks after
vaccination, woodchucks were challenged intravenously with an inoculum
containing 105 WHV genome equivalents. Serum derived from a
chronic WHV carrier was used as a source of WHV. This serum contained
107 WHV genome equivalents per ml. The serum was sterile
filtered, and aliquots were stored at
80°C. In previous
experiments, similar doses of this stock have been used to challenge 14 woodchucks (22; our unpublished observations). All animals
became viremic after challenge. These animals were included in the
statistical analysis. The significance for the 2 × 2 table was
calculated using a formula for small sample sizes:
Pi+1=[ai×di/(bi+1×ci+1)]×Pi (10).
Serology and detection of WHV DNA.
Anti-WHc, anti-WHs, and
WHsAg were detected by enzyme-linked immunosorbent assay (ELISA) as
described previously (27, 28) The sensitivity of ELISA was
determined in tests of serially diluted positive sera of woodchucks
experimentally infected with WHV. The ELISA for anti-WHc was able to
detect anti-WHc in woodchuck sera at dilutions of 10
3 to
10
6. The dot blot technique was routinely performed to
detect WHV DNA in woodchuck sera. For PCR detection of WHV DNA in
woodchuck sera, nucleic acids were isolated from sera by proteinase K
digestion and phenol extraction. PCR for amplification of the WHV core
gene was performed with primers wc1 (nucleotides nt 2015 to 2038, 5'-TGGGGCCATGGACATAGATCCTTA-3') and fwc3a (nt 2537 to 2557, 5'-TCTGCGACGCGGTGATTGAGA-3'). By testing serial dilutions of
a cloned WHV core fragment, 10 copies of specific templates were
sufficient to give a positive result in the PCR. A virus DNA titer of
500 copies per ml of serum could be detected.
Measurement of WHV antigen-specific proliferation of woodchuck
PBMCs.
Antigen-specific proliferation of woodchuck peripheral
blood mononuclear cells (PBMCs) was determined by
[2-3H]adenine assay as described previously
(16). Briefly, woodchuck PBMCs were separated by
Ficoll-Paque (Pharmacia, Freiburg, Germany) density gradient
centrifugation and suspended in 0.9% NaCl. Triplicates of 5 × 104 PBMCs were cultured in flat-bottom 96-well microtiter
plates (Falcon; Becton Dickinson, Paramus, N.J.) at 37°C in a
humidified atmosphere containing 5% CO2. Two hundred
microliters of AIM-V medium (Gibco BRL) supplemented with 2% 0.2 M
L-glutamine (Sigma), 1% 0.125 M gentamicin sulfate
(Sigma), and 10% fetal calf serum (Gibco BRL) was added to each well.
PBMC proliferation in response to WHcAg or peptides was measured at an
antigen concentration of 1 µg/ml. After a 5-day incubation, cells
were labeled with 1 µCi of [2-3H]adenine (Amersham,
Braunschweig, Germany) for 20 h and collected by a cell harvester
(Skatron). Two panels, A and B, of WHcAg-derived peptides were used
(see Table 2). Panel A consists of 16 overlapping 20-mer peptides and
covers the complete WHcAg. Panel B, consisting of 6 additional
peptides, covers the immunodominant region of the WHcAg, amino acids
(aa) 97 to 140.
Results for triplicate cultures are presented as a mean stimulation
index (SI, mean total absorption for stimulated PBMCs
divided by the
mean total absorption for control). The standard
deviation of the means
was less than 30% of the mean (range, 15
to 50%). An SI of

2 was
considered significant, to distinguish
the specific stimulation and
possible variation within an assay,
as described previously
(
24).
 |
RESULTS |
Immune response succeeding a single-shot DNA
vaccination.
To test whether a single-shot DNA vaccination
induced an efficient immune response, three woodchucks (group A)
were immunized with 10 µg of an expression vector for WHcAg
(pWHcIm) using the gene gun (Table 1). To
evaluate the augmentation of immune response by coadministration
of an expression vector for IFN-
, three woodchucks (group B) were
immunized with 10 µg of pWHcIm and 10 µg of pWIFN-
. Sera
were tested for anti-WHcAg and for proliferative responses of
PBMCs to WHcAg and WHcAg-derived peptides (Table
2) after vaccination. Woodchucks of group
A immunized with pWHcIm developed neither anti-WHcAg (Fig.
1A) nor a proliferative response to WHcAg or core peptides (Fig. 2). Likewise, no
antibody response to WHcAg was induced by immunization of animals in
group B with pWHcIm in combination with pWIFN-
(Fig. 1B). However,
for all animals in group B, a proliferative response to core and core
peptides was detected at week 3 after immunization (Fig. 2). At this
time point, PBMCs derived from animals 9221 and 9226 proliferated in response to peptide 19 (aa 111 to 124), located in the middle of WHcAg.
Additionally, animal 9226 showed a proliferation in response to peptide
8, and animal 9221 responded to WHcAg. Six weeks after immunization, a
multispecific response against WHcAg and WHcAg-derived peptides was
detected in all animals in group B. PBMCs obtained from the control
animals vaccinated with the empty plasmid pcDNA3 did not show a
proliferative response to WHcAg or core peptides after immunization.



View larger version (146K):
[in this window]
[in a new window]
|
FIG. 1.
Serological profiles of woodchucks after immunization
and WHV challenge. (A) Woodchucks immunized with pWHcIm. (B) Woodchucks
immunized with pWHcIm and pWIFN- . (C) Woodchucks immunized with the
control plasmid pcDNA3. The woodchucks were immunized at week 6 and
challenged at week 0, as indicated. Antibody reactivity of woodchuck
sera to WHsAg (open square) or WHcAg (black square) is shown. The
presence of WHV DNA is indicated by a black plus sign for PCR positive
and by a white plus sign for PCR and dot blot hybridization positive.
Dot blot hybridization was carried out using the titration of a
standard (1010 to 106 copies/ml) and comparing
the signals to the experimental signals. All detected signals were in
the 106 range except for those of animal 9936 in week 4 (107 copies/ml) and animal 9993 in week 4 (107
copies/ml).
|
|

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 2.
Lymphoproliferative responses to WHcAg and WHcAg-derived
peptides during the immunization study. Positive results (SI > 3)
are indicated by boxes. Numbers stand for peptides as shown in Table 2.
C, WHcAg.
|
|
Magnitude of the proliferative immune response after
immunization.
The protective efficacy of DNA vaccination may be
correlated to the intensity of the lymphoproliferative response.
Therefore, the magnitude of the proliferative immune response was
analyzed after vaccination. The proliferative immune response induced
by coimmunization with core and IFN-
6 weeks after vaccination was compared to the proliferative response detected in the control animals
6 weeks after WHV infection (Fig. 3). The
SI of PBMCs derived from animals of group B ranged from 3 to 5. The
strongest proliferation (SI > 5) was detected in PBMCs of animal
9222 in response to peptide 11. A proliferative response of the same
magnitude was demonstrated with PBMCs derived from the control animals
6 weeks after WHV inoculation.

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 3.
Magnitude of T-cell proliferation induced by the
combination vaccination. Lymphocytes derived from vaccinated and
challenged woodchucks were stimulated with WHcAg and WHcAg-derived
peptides. Results for PBMCs (triplicates) are presented as mean SI.
|
|
Challenge of vaccinated animals with WHV.
Woodchucks of all
groups were challenged with 105 genome equivalents of WHV 6 weeks after the single-shot immunization, and sera were analyzed for
WHV DNA by dot blot hybridization as well as by PCR and for antibodies
against WHcAg. WHV DNA was detected in the sera from two animals of
group A (10841, 10842), while the third animal (10843) stayed negative
for viral DNA throughout the follow-up (Fig. 1A). Animal 10841 was PCR
positive at week 5 after challenge and animal 10842 was positive at
weeks 3 and 4 after challenge. However, WHV DNA could not be detected
by dot blot hybridization in the sera of these animals, indicating that the number of WHV genomes stayed below the detection limit of 106 genomes per ml. The observed protection of one of three
animals without detectable WHV DNA was not significant (P = 0.2). In contrast to animals in group A, all animals in group B
immunized with pWHcIm in combination with pWIFN-
remained negative
for WHV throughout the observation period (Fig. 1B). Neither by
dot blot hybridization nor by PCR could WHV DNA be detected.
Animals in this group were significantly protected
(P = 0.0015) from viremia. As expected, the two
control animals of group C, immunized with the empty pcDNA3 vector,
were viremic after inoculation of infectious WHV (Fig. 1C). WHV DNA was
repeatedly detected by PCR in the serum of animal 9936 between weeks 2 and 6 after infection, while animal 9993 was PCR positive only in week
4. In both animals, WHV DNA was detected by dot blot hybridization 4 weeks after challenge with a titer of 107 genomes per ml of serum.
Humoral immune response after challenge.
Antibodies
against WHsAg and WHcAg were determined following the inoculation
of WHV. All animals of group A developed antibodies against WHcAg after
challenge (Fig. 1A). Additionally, antibodies against WHsAg were
detected at weeks 3 and 4 after challenge in the sera of animals 10841 and 10842. Although no WHV DNA could be detected in the serum of
woodchuck 10843 3 weeks after challenge, the animal seroconverted to
anti-WHsAg. Even though a proliferative response to WHcAg and
WHcAg-derived peptides was detected after immunization with
pWHcIm and pWIFN-
, no anamnestic humoral immune response to WHcAg
was observed in animals of group B seroconverting (
50% inhibition)
between weeks 6 and 8 after challenge (Fig. 1B). Furthermore, all
animals, including the WHV DNA-negative animals, seroconverted to
anti-HBsAg, indicating a low-level infection of the liver.
Woodchucks 9222 and 9226 of group B displayed a delayed
seroconversion to anti-WHsAg (weeks 9 and 10 after challenge) and to
anti-WHcAg (weeks 8 and 9 after challenge) when compared to control
animals. The two control animals, immunized with the empty pcDNA3
vector, seroconverted to anti-WHcAg and anti-WHsAg between 4 and
6 weeks after challenge, respectively (Fig. 1C).
Lymphoproliferative response after challenge.
The cellular
immune response to WHcAg and WHcAg-derived peptides was determined by
proliferation assay after challenge. Two animals of group A
immunized with pWHcIm developed a proliferative response to WHcAg and
various core peptides after challenge (Fig. 2). Simultaneous to the
detection of WHV DNA in the serum of woodchuck 10841 in week 4 after
infection, PBMCs derived from this animal showed an initial
proliferative response. The proliferative response was directed against
WHcAg, peptide 19, located within the middle part of the core protein,
and peptide 1, located at the amino terminus. PBMCs derived from
woodchuck 10842 showed a multispecific proliferative response to WHcAg,
to peptide 6, and to peptides covering aa 97 to 137 of the core protein
in weeks 4 and 5 after challenge (Fig. 2). The third woodchuck of group
A (10843) did not show a proliferative response to WHcAg or core
peptides. The proliferative responses of animals 10841 and 10842 of
group A did not show major differences in time of occurrence and
peptides recognized from the proliferative responses of the control
animals. The proliferative response to WHcAg or core peptides of PBMCs derived from animals of group B seen at week 3 after vaccination was
present up to weeks 1 and 2 after challenge. However, they did not show
a proliferative response 4 and 5 weeks after challenge, whereas at that
time the two control animals developed a proliferative response.
 |
DISCUSSION |
In this study, we have demonstrated that a combined DNA
vaccination of plasmids expressing WHcAg and IFN-
using the gene gun
is sufficient to induce an immune response and to control WHV
replication in woodchucks after challenge.
The lymphoproliferative responses to WHcAg in vaccinated woodchucks are
closely associated with effective control of WHV infection. Menne et
al. demonstrated that priming T-cell response to a single epitope
within WHcAg by peptide immunization was sufficient to control WHV
infection (24). However, the protective efficacy of DNA
vaccination may be linked to the potency of the lymphoproliferative response. Therefore, the magnitude of the proliferative response was
analyzed after vaccination. The lymphoproliferative response after
combined DNA vaccination with core antigen and IFN-
was as strong as
the proliferative response induced by viral replication following
experimental WHV infection. These results are in accordance with
previously published experiments showing that the coadministration of
IFN-
leads to an enhanced proliferative response and a reduced antibody response to HBsAg in mice (3). In this study,
PBMCs derived from three animals immunized with core antigen and
IFN-
showed strong proliferation in response to WHcAg. All three
animals were protected from viremia. These results corroborate the
importance of WHcAg-specific lymphoproliferative responses in the
control of WHV infection. In woodchucks immunized with pWHcIm alone,
viremia occurred but remained low. In woodchuck 10843, WHV DNA was
below the PCR detection limit. Thus, vaccination with pWHcIm alone may induce a weak immune response, which was generally insufficient to
control WHV infection in woodchucks. We have demonstrated previously that the viremic phase in woodchucks acutely infected with WHV is
accompanied by a proliferative response to WHcAg and core-derived peptides (23). Accordingly, all viremic animals of groups
A and C showed a proliferative response to WHcAg and different
core-derived peptides 4 to 7 weeks after challenge. A proliferative
response was also demonstrated in all animals of group B 3 weeks prior to challenge and between 1 and 2 weeks after challenge. This response can be attributed to the previous vaccination. However, animal 10843 was also protected but did not show any measurable lymphoproliferative responses to WHcAg; although it applies to only one animal, this observation may suggest that other cellular immune responses such as
cytotoxic T lymphocyte may be involved in the protective mechanism. Nevertheless, these results provide additional evidence for the importance of WHcAg-specific lymphoproliferative responses in WHV infection.
Woodchucks develop high antibody titers against WHcAg during a natural
WHV infection, although WHcAg is primarily localized intracellularly
(5, 12). However, no anti-WHcAg was detected after DNA
vaccination with 10 µg of plasmid, even by using core antigen in
combination with IFN-
. Previously, we had vaccinated woodchucks
intramuscularly with different plasmid doses (22). Immunization with 100 µg of plasmid DNA did not induce measurable anti-WHcAg antibody titers. Only after three injections using 1-mg DNA
doses was a low, transient antibody titer to WHcAg detected. It appears
that DNA vaccination was unable to induce an antibody response to WHcAg
in woodchucks. An interesting observation in our experiments is the
lack of anamnestic antibody responses against WHcAg after challenge in
animals of groups A and B immunized with pWHcIm. We have demonstrated
previously that intramuscular vaccination with pWHcIm induces low
titers of anti-WHcAg and a slight increase in anti-WHcAg titers after
challenge with WHV (22). However, this increase was
probably due to the carryover from the high anti-WHcAg antibody titer
in the challenge virus stock. In contrast, a strong anamnestic antibody
response to WHsAg after challenge was observed with woodchucks
previously immunized with a vector expressing WHsAg. A strong
anamnestic humoral immune response was also observed after boosting
chimpanzees immunized with a single injection of 400 µg of plasmid
DNA expressing HBsAg (6). These results indicate that the
development of antibodies against WHcAg and WHsAg is controlled by
distinct mechanisms. This may be explained by different cellular
locations of these antigens, which influence their exposure to B cells.
WHcAg is a nucleoprotein and does not induce neutralizing
antibodies against WHV virions. Thus, vaccinations with WHcAg or plasmids expressing WHcAg do not protect hepatocytes from viral infection and do not induce a "sterile" immunity. However, viral replication can be suppressed efficiently at an early stage of infection. Roos et al. demonstrated that the suppression of WHV replication in WHcAg-immunized animals is so effective that the virus
cannot be detected in liver biopsies (27). Hence the
cell-mediated immunity primed by DNA vaccination apparently controlled
the infection and significantly reduced the release of virus particles
into the periphery. Because there is a strong correlation between
anti-surface antibodies and protection in humans and in woodchucks, the
appearance of anti-surface antibodies always indicates a termination of
the infection. Even though the presence of anti-surface antibodies and
virus may occasionally overlap for a short period, significant viral
replication has never been observed in the presence of anti-surface antibodies. Woodchucks immunized with inactivated serum derived from
chronic WHV carriers do not develop anti-WHsAg (our unpublished observations). Therefore, the presence of antibodies against WHsAg found in woodchucks coimmunized with plasmids expressing WHcAg and
IFN-
after challenge indicates a low-level replication in hepatocytes after challenge with WHV. Neutralizing antibodies, such as
anti-HBsAg antibodies, are important to prevent the spread of released
WHV to uninfected hepatocytes, while the cellular immune response
system primed by DNA vaccination may down regulate intrahepatic WHV replication.
Taken together, our findings demonstrate that DNA covaccination with
WHcAg and IFN-
expression plasmids induces a protective immune
response in woodchucks. Coadministration of IFN-
enhanced the
priming of cellular immune responses substantially and appeared to be
essential for the control of WHV replication. These observations therefore have implications for the development of novel DNA vaccines for prophylaxis and therapeutic treatments against HBV infection.
 |
ACKNOWLEDGMENTS |
We are grateful to Jörg Reimann and Reinhold Schirmbeck for
helpful discussions and advice. We thank Thekla Kemper for excellent technical assistance.
This work is supported by grants of the German Bundesministerium
für Bildung und Forschung to M.R. and M.L. (BMBF, 01GE96125) and
to M.L. and M.R. (BMBF, 01GE9909).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Institut
für Virologie, Universitätsklinikum Essen,
Hufelandstrasse 55, 45122 Essen, Germany. Phone: 49 201 723 3550. Fax:
49 201 723 5929. E-mail: roggendorf{at}uni-essen.de.
 |
REFERENCES |
| 1.
|
Bohm, W.,
A. Kuhrober,
T. Paier,
T. Mertens,
J. Reimann, and R. Schirmbeck.
1996.
DNA vector constructs that prime hepatitis B surface antigen-specific cytotoxic T lymphocyte and antibody responses in mice after intramuscular injection.
J. Immunol. Methods
193:29-40[CrossRef][Medline].
|
| 2.
|
Bohm, W.,
T. Mertens,
R. Schirmbeck, and J. Reimann.
1998.
Routes of plasmid DNA vaccination that prime murine humoral and cellular immune responses.
Vaccine
16:949-954[CrossRef][Medline].
|
| 3.
|
Chow, Y. H.,
B. L. Chiang,
Y. L. Lee,
W. K. Chi,
W. C. Lin,
Y. T. Chen, and M. H. Tao.
1998.
Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes.
J. Immunol.
160:1320-1329[Abstract/Free Full Text].
|
| 4.
|
Chow, Y. H.,
W. L. Huang,
W. K. Chi,
Y. D. Chu, and M. H. Tao.
1997.
Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2.
J. Virol.
71:169-178[Abstract/Free Full Text].
|
| 5.
|
Cote, P. J.,
C. Roneker,
K. Cass,
F. Schodel,
D. Peterson,
B. Tennant,
F. De Noronha, and J. Gerin.
1993.
New enzyme immunoassays for the serologic detection of woodchuck hepatitis virus infection.
Viral Immunol.
6:161-169[Medline].
|
| 6.
|
Davis, H. L.,
M. J. McCluskie,
J. L. Gerin, and R. H. Purcell.
1996.
DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines.
Proc. Natl. Acad. Sci. USA
93:7213-7218[Abstract/Free Full Text].
|
| 7.
|
Davis, H. L., and R. G. Whalen.
1995.
DNA-based immunization.
Mol. Cell. Biol. Hum. Dis.
5:368-387.
|
| 8.
|
Donnelly, J. J.,
J. B. Ulmer,
J. W. Shiver, and M. A. Liu.
1997.
DNA vaccines.
Annu. Rev. Immunol.
15:617-648[CrossRef][Medline].
|
| 9.
|
Farrar, M. A., and R. D. Schreiber.
1993.
The molecular cell biology of interferon-gamma and its receptor.
Annu. Rev. Immunol.
11:571-611[CrossRef][Medline].
|
| 10.
|
Feldman, S., and E. Klinger.
1963.
Short cut evaluation of Fisher-Yates "excat test."
Psychometrika
28:289-291[CrossRef].
|
| 11.
|
Geissler, M.,
A. Gesien, and J. R. Wands.
1997.
Inhibitory effects of chronic ethanol consumption on cellular immune responses to hepatitis C virus core protein are reversed by genetic immunizations augmented with cytokine-expressing plasmids.
J. Immunol.
159:5107-5113[Abstract].
|
| 12.
|
Guidotti, L. G.,
V. Martinez,
Y. T. Loh,
C. E. Rogler, and F. V. Chisari.
1994.
Hepatitis B virus nucleocapsid particles do not cross the hepatocyte nuclear membrane in transgenic mice.
J. Virol.
68:5469-5475[Abstract/Free Full Text].
|
| 13.
|
Johnston, S. A., and D. C. Tang.
1994.
Gene gun transfection of animal cells and genetic immunization.
Methods Cell Biol.
43A:353-365.
|
| 14.
|
Kim, J. J.,
L. K. Nottingham,
A. Tsai,
D. J. Lee,
H. C. Maguire,
J. Oh,
T. Dentchev,
K. H. Manson,
M. S. Wyand,
M. G. Agadjanyan,
K. E. Ugen, and D. B. Weiner.
1999.
Antigen-specific humoral and cellular immune responses can be modulated in rhesus macaques through the use of IFN-gamma, IL-12, or IL-18 gene adjuvants.
J. Med. Primatol.
28:214-223[Medline].
|
| 15.
|
Kim, J. J.,
K. A. Simbiri,
J. I. Sin,
K. Dang,
J. Oh,
T. Dentchev,
D. Lee,
L. K. Nottingham,
A. A. Chalian,
D. McCallus,
R. Ciccarelli,
M. G. Agadjanyan, and D. B. Weiner.
1999.
Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV.
J. Interferon Cytokine Res.
19:77-84[CrossRef][Medline].
|
| 16.
|
Kreuzfelder, E.,
S. Menne,
S. Ferencik,
M. Roggendorf, and H. Grosse-Wilde.
1996.
Assessment of peripheral blood mononuclear cell proliferation by [2-3H]adenine uptake in the woodchuck model.
Clin. Immunol. Immunopathol.
78:223-227[CrossRef][Medline].
|
| 17.
|
Kuhrober, A.,
H. P. Pudollek,
K. Reifenberg,
F. V. Chisari,
H. J. Schlicht,
J. Reimann, and R. Schirmbeck.
1996.
DNA immunization induces antibody and cytotoxic T cell responses to hepatitis B core antigen in H-2b mice.
J. Immunol.
156:3687-3695[Abstract].
|
| 18.
|
Kuhrober, A.,
J. Wild,
H. P. Pudollek,
F. V. Chisari, and J. Reimann.
1997.
DNA vaccination with plasmids encoding the intracellular (HBcAg) or secreted (HBeAg) form of the core protein of hepatitis B virus primes T cell responses to two overlapping Kb- and Kd-restricted epitopes.
Int. Immunol.
9:1203-1212[Abstract/Free Full Text].
|
| 19.
|
Kupper, T. S.
1990.
The activated keratinocyte: a model for inducible cytokine production by non-bone marrow-derived cells in cutaneous inflammatory and immune responses.
J. Investig. Dermatol.
94:S146-S150[CrossRef].
|
| 20.
|
Leitner, W. W.,
M. C. Seguin,
W. R. Ballou,
J. P. Seitz,
A. M. Schultz,
M. J. Sheehy, and J. A. Lyon.
1997.
Immune responses induced by intramuscular or gene gun injection of protective deoxyribonucleic acid vaccines that express the circumsporozoite protein from Plasmodium berghei malaria parasites.
J. Immunol.
159:6112-6119[Abstract].
|
| 21.
|
Lohrengel, B.,
M. Lu, and M. Roggendorf.
1998.
Molecular cloning of the woodchuck cytokines: TNF-alpha, IFN-gamma, and IL-6.
Immunogenetics
47:332-335[CrossRef][Medline].
|
| 22.
|
Lu, M.,
G. Hilken,
J. Kruppenbacher,
T. Kemper,
R. Schirmbeck,
J. Reimann, and M. Roggendorf.
1999.
Immunization of woodchucks with plasmids expressing woodchuck hepatitis virus (WHV) core antigen and surface antigen suppresses WHV infection.
J. Virol.
73:281-289[Abstract/Free Full Text].
|
| 23.
|
Menne, S.,
J. Maschke,
M. Lu,
H. Grosse-Wilde, and M. Roggendorf.
1998.
T-cell response to woodchuck hepatitis virus (WHV) antigens during acute self-limited WHV infection and convalescence and after viral challenge.
J. Virol.
72:6083-6091[Abstract/Free Full Text].
|
| 24.
|
Menne, S.,
J. Maschke,
T. K. Tolle,
M. Lu, and M. Roggendorf.
1997.
Characterization of T-cell response to woodchuck hepatitis virus core protein and protection of woodchucks from infection by immunization with peptides containing a T-cell epitope.
J. Virol.
71:65-74[Abstract/Free Full Text].
|
| 25.
|
Montgomery, D. L.,
J. B. Ulmer,
J. J. Donnelly, and M. A. Liu.
1997.
DNA vaccines.
Pharmacol. Ther.
74:195-205[CrossRef][Medline].
|
| 26.
|
Pertmer, T. M.,
M. D. Eisenbraun,
D. McCabe,
S. K. Prayaga,
D. H. Fuller, and J. R. Haynes.
1995.
Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA.
Vaccine
13:1427-1430[CrossRef][Medline].
|
| 27.
|
Roos, S.,
K. Fuchs, and M. Roggendorf.
1989.
Protection of woodchucks from infection with woodchuck hepatitis virus by immunization with recombinant core protein.
J. Gen. Virol.
70:2087-2095[Abstract/Free Full Text].
|
| 28.
|
Schodel, F.,
G. Neckermann,
D. Peterson,
K. Fuchs,
S. Fuller,
H. Will, and M. Roggendorf.
1993.
Immunization with recombinant woodchuck hepatitis virus nucleocapsid antigen or hepatitis B virus nucleocapsid antigen protects woodchucks from woodchuck hepatitis virus infection.
Vaccine
11:624-628[CrossRef][Medline].
|
| 29.
|
Steinman, R. M.
1991.
The dendritic cell system and its role in immunogenicity.
Annu. Rev. Immunol.
9:271-296[CrossRef][Medline].
|
| 30.
|
Tang, D. C.,
M. DeVit, and S. A. Johnston.
1992.
Genetic immunization is a simple method for eliciting an immune response.
Nature
356:152-154[CrossRef][Medline].
|
| 31.
|
Torres, C. A.,
A. Iwasaki,
B. H. Barber, and H. L. Robinson.
1997.
Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations.
J. Immunol.
158:4529-4532[Abstract].
|
| 32.
|
Triyatni, M.,
A. R. Jilbert,
M. Qiao,
D. S. Miller, and C. J. Burrell.
1998.
Protective efficacy of DNA vaccines against duck hepatitis B virus infection.
J. Virol.
72:84-94[Abstract/Free Full Text].
|
| 33.
|
Whalen, R. G.
1996.
DNA vaccines for emerging infectious diseases: what if?
Emerg. Infect. Dis.
2:168-175[Medline].
|
| 34.
|
Whalen, R. G.,
C. Leclerc,
E. Deriaud,
R. Schirmbeck,
J. Reimann, and H. L. Davis.
1995.
DNA-mediated immunization to the hepatitis B surface antigen. Activation and entrainment of the immune response.
Ann. N. Y. Acad. Sci.
772:64-76[Medline].
|
| 35.
|
Wild, J.,
B. Gruner,
K. Metzger,
A. Kuhrober,
H. P. Pudollek,
H. Hauser,
R. Schirmbeck, and J. Reimann.
1998.
Polyvalent vaccination against hepatitis B surface and core antigen using a dicistronic expression plasmid.
Vaccine
16:353-360[CrossRef][Medline].
|
Journal of Virology, June 2001, p. 5036-5042, Vol. 75, No. 11
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.11.5036-5042.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Lu, M., Yao, X., Xu, Y., Lorenz, H., Dahmen, U., Chi, H., Dirsch, O., Kemper, T., He, L., Glebe, D., Gerlich, W. H., Wen, Y., Roggendorf, M.
(2008). Combination of an Antiviral Drug and Immunomodulation against Hepadnaviral Infection in the Woodchuck Model. J. Virol.
82: 2598-2603
[Abstract]
[Full Text]
-
Wang, J., Gujar, S. A., Cova, L., Michalak, T. I.
(2007). Bicistronic Woodchuck Hepatitis Virus Core and Gamma Interferon DNA Vaccine Can Protect from Hepatitis but Does Not Elicit Sterilizing Antiviral Immunity. J. Virol.
81: 903-916
[Abstract]
[Full Text]
-
Lu, M., Isogawa, M., Xu, Y., Hilken, G.
(2005). Immunization with the Gene Expressing Woodchuck Hepatitis Virus Nucleocapsid Protein Fused to Cytotoxic-T-Lymphocyte-Associated Antigen 4 Leads to Enhanced Specific Immune Responses in Mice and Woodchucks. J. Virol.
79: 6368-6376
[Abstract]
[Full Text]
-
Thermet, A., Robaczewska, M., Rollier, C., Hantz, O., Trepo, C., Deleage, G., Cova, L.
(2004). Identification of Antigenic Regions of Duck Hepatitis B Virus Core Protein with Antibodies Elicited by DNA Immunization and Chronic Infection. J. Virol.
78: 1945-1953
[Abstract]
[Full Text]
-
van Rooij, E. M. A., Glansbeek, H. L., Hilgers, L. A. T., te Lintelo, E. G., de Visser, Y. E., Boersma, W. J. A., Haagmans, B. L., Bianchi, A. T. J.
(2002). Protective Antiviral Immune Responses to Pseudorabies Virus Induced by DNA Vaccination Using Dimethyldioctadecylammonium Bromide as an Adjuvant. J. Virol.
76: 10540-10545
[Abstract]
[Full Text]
-
Lu, M., Lohrengel, B., Hilken, G., Kemper, T., Roggendorf, M.
(2002). Woodchuck Gamma Interferon Upregulates Major Histocompatibility Complex Class I Transcription but Is Unable To Deplete Woodchuck Hepatitis Virus Replication Intermediates and RNAs in Persistently Infected Woodchuck Primary Hepatocytes. J. Virol.
76: 58-67
[Abstract]
[Full Text]